
Dr. Heidi Overton, President Donald Trump’s nominee to lead the Food and Drug Administration, faced a grueling two-hour confirmation hearing on Thursday as senators from both sides of the aisle demanded answers on hot-button issues like childhood vaccines and access to the abortion pill mifepristone.
Appearing before the Senate Health, Education, Labor, and Pensions (HELP) Committee, Overton—a physician and domestic policy adviser to Trump—repeatedly relied on technical definitions of her prospective role, frustrating lawmakers who sought her direct professional opinions.
If confirmed, she will take the helm of an agency that has been led by acting commissioner Kyle Diamantas since the resignation of Dr. Martin Makary in May.
Navigating Vaccine Controversies
A primary flashpoint during the hearing involved the president’s recent rhetoric regarding childhood immunizations.
Committee Chairman Bill Cassidy (R-La.) pointedly asked Overton if the measles, mumps, and rubella (MMR) vaccine is safe, referencing Trump’s false claim in August that the shot is “potentially quite lethal”. Overton confirmed that the MMR vaccine is “safe and effective,” calling it the best tool for public health responses. However, when pressed by Democratic senators to explicitly admit that the president was wrong, she repeatedly demurred, stating instead that her role would be to ensure Americans know the status of FDA-approved products.
“This committee needs to know whether you will be radically honest, whether you will use your authority to stand up for sound science and protect children’s health,” Cassidy warned.
The Abortion Pill and FDA Independence
Overton also faced intense questioning regarding mifepristone, the nation’s principal abortion medication.
Before joining the administration, Overton co-authored a policy paper for the conservative America First Policy Institute, labeling telemedicine access for abortion as “dangerous to women”. When Sens. Patty Murray (D-Wash.) and Tammy Baldwin (D-Wis.) asked whether she personally believed the drug is safe, Overton sidestepped. She noted that mifepristone has met the FDA’s statutory standards for safety and efficacy, adding that she would not “prejudge” the agency’s ongoing internal review of the medication.
Her non-committal answers drew the ire of lawmakers, including Sen. Lisa Murkowski (R-Alaska), who expressed frustration over Overton’s highly technical, evasive responses.
Beyond reproductive rights and vaccines, Overton pledged to implement regulatory reforms aimed at countering China’s rapidly growing biotechnology sector and accelerating early drug research. She now awaits a final committee vote, where her answers will be heavily weighed by moderate Republicans whose support is crucial to her confirmation.

